エリスロポエチン投与時の貧血の改善と血管内皮障害

秋葉 隆; 立花 健; 出口文 佐栄; 坂本 尚登; 安藤 亮一; 桜井 俊一; 千田 佳子; 戸村 成男; 吉山 直樹; 星野 正信; 丸茂 文昭

doi:10.11392/jsao1972.21.850

ERYTHROPOIETIN ADMINISTRATION FOR RENAL ANEMIA MAY INCREASE COAGULABILITY AND ENDOTHELIAL CELL INJURY?

T. AKIBA, K. TACHIBANA, F. DEGUCHI, N. SAKAMOTO, R. ANDO, S. SAKURAI, Y. CHIDA, N. TOMURA, N. YOSHIYAMA, M. HOSHINO, F. MARUMO

Author information

T. AKIBA
Department of Internal Medicine Tokyo Medicaland Dental University
KidneyCenter
K. TACHIBANA
Department of Internal Medicine Tokyo Medicaland Dental University
KidneyCenter
F. DEGUCHI
Nakano General Hospital
N. SAKAMOTO
Department of Internal Medicine Tokyo Medicaland Dental University
KidneyCenter
R. ANDO
Nakano General Hospital
S. SAKURAI
Mishima Hospital
Y. CHIDA
Nakano General Hospital
Nakano Clinic
N. TOMURA
Nakano General Hospital
N. YOSHIYAMA
Mishima Hospital
M. HOSHINO
Hijiribashi Clinic.
F. MARUMO
Department of Internal Medicine Tokyo Medicaland Dental University

Keywords: Erythropoietin, vasoactive hormone, endothelial cell injury, thrombolysis

JOURNAL FREE ACCESS

1992 Volume 21 Issue 3 Pages 850-854

DOI https://doi.org/10.11392/jsao1972.21.850

Details

Abstract

We estimated the effects of long-term erythropoietin (EPO) administration to hemodialysis patients (HD Pts) on endothelial cell injury. Thirty HD Pts were administered EPO for 12 weeks. Hematocrit increased from 6.4 to 9.5g/dl. Blood pressure did not change. Plasma Endothelin decreased from 24.9±8.6pg/ml to 14.7±3.4pg/ml. ANP, ALD, PRA, ATII, and ADH did not change. Protein C and S significantly decreased at 4 weeks. We conclude that EPO did not abbreviate endothelial cell injury.

Corresponding author

Register with J-STAGE for free!